Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Belcesiran (DCR-HBVS) in Healthy Volunteers and Chronic Hepatitis B
NCT03772249Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2018
- Primary completion
- Jul 2022
- Modality
- Gene Editing, Antisense DNA, Gene Silencing
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of belcesiran in Chronic Hepatitis B (CHB) (8 arms), sponsored by Novo Nordisk. Primary endpoint: Adverse Events at 16 weeks. Started Dec 2018; status: completed.
02
Drugs
belcesiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03772249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772249.